The 52-Week Low Club

Investing

February 9, 2009 4:28 pm

Last Updated: March 23, 2020 12:50 pm

ViroPharma (VPHM) Drug trial fails. Huge drop to $4.89 from 52-week high of $15.16.

Insight Enterprises (NSIT) Plans to restate earnings. Falls to $2.69 from 52-week high of $19.25.

Popular Inc (BPOP) Concerns bank could fail.

Douglas A. McIntyre

Read more: Investing, BPOP, VPHM, Active Trader

Editors' Picks